Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several efficacy/indication claims are supported (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis), but many safety-related assertions (neurologic, ocular, hepatic, malignancy, cardiovascular) are not supported by the provided label excerpts. Some statements are overbroad or include specific named conditions not evidenced in the supplied text.
Category Scores
Accurate Statements
Cosentyx is approved for the treatment of moderate to severe plaque psoriasis.
Indications and Usage 1.1
Cosentyx is approved for the treatment of psoriatic arthritis.
Indications and Usage 1.2
Cosentyx is approved for the treatment of ankylosing spondylitis.
Indications and Usage 1.3
Cosentyx may increase the risk of infections, including upper respiratory tract infections.
Warnings and Precautions 5.1 and Patient Counseling/Instructions 17
Some patients have experienced allergic reactions, including anaphylaxis, after taking Cosentyx.
Warnings and Precautions 5.2
Patients should be monitored for signs of infection, such as fever and cough, while taking Cosentyx.
Warnings and Precautions 5.1 and Patient Counseling/Instructions 17
There is limited data on the use of Cosentyx during pregnancy.
Use in Specific Populations 8.1
Unsupported Statements
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A).
No relevant information provided in the supplied label sections.
By blocking IL-17A, Cosentyx reduces inflammation and slows down disease progression in patients with autoimmune diseases.
No relevant efficacy/mechanism statements provided in the supplied label sections.
Cosentyx is approved for the treatment of axial spondyloarthritis.
Provided label support is limited to active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation; the statement is broader.
Some patients have experienced worsening of arthritis symptoms, including joint pain and swelling, after starting Cosentyx.
No relevant adverse-effect information provided in the supplied label sections.
In rare cases, Cosentyx has been associated with the development of new psoriasis lesions or worsening of existing lesions.
No relevant adverse-effect information provided in the supplied label sections.
Rare cases of neurological side effects, such as seizures, have been reported in patients taking Cosentyx.
No neurological/seizure information provided in the supplied label sections.
Cosentyx may increase the risk of eye problems, including uveitis and conjunctivitis.
No ophthalmic/uveitis/conjunctivitis information provided in the supplied label sections.
In rare cases, Cosentyx has been associated with liver damage, including elevated liver enzymes and liver failure.
No hepatic/liver damage information provided in the supplied label sections.
Reports of malignancies, including lymphoma and leukemia, have occurred in patients taking Cosentyx.
No malignancy information provided in the supplied label sections.
Cosentyx may increase the risk of serious infections, including sepsis and meningitis.
Label support provided discusses serious/fatal opportunistic infections, but sepsis and meningitis are not specifically supported in the supplied excerpts.
Rare cases of cardiovascular events, including heart attack and stroke, have been reported in patients taking Cosentyx.
No cardiovascular information provided in the supplied label sections.
Regular blood tests are recommended to check for liver damage and other side effects in patients taking Cosentyx.
No laboratory monitoring/blood test recommendations for liver damage are provided in the supplied label sections.
Regular eye exams are recommended to check for eye problems in patients taking Cosentyx.
No eye exam/monitoring recommendations provided in the supplied label sections.
Patients should be monitored for neurological side effects, such as seizures, while taking Cosentyx.
No neurologic monitoring/seizure monitoring recommendations provided in the supplied label sections.
Cosentyx may interact with other medications, including immunosuppressants and biologics.
Provided drug-interaction excerpt addresses CYP450 substrate monitoring/dose adjustment; immunosuppressants/biologics are not specifically evidenced in the supplied sections.
Contradictions
Important Omissions
Boxed warning, contraindications, and full warnings/precautions content could not be evaluated because those sections were not provided in the prompt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple safety claims (neurologic, ocular, hepatic, malignancy, cardiovascular) are not supported by the provided label excerpts, which could mislead about labeled risks; infection and hypersensitivity monitoring claims are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many safety and mechanism details are not supported by the supplied label excerpts; some statements are overbroad or include specific conditions not evidenced (e.g., sepsis/meningitis, axial spondyloarthritis broadly).
Suggested Improvement
Restrict safety statements to those explicitly present in the provided Warnings/Precautions and Adverse Reactions excerpts, and align axial spondyloarthritis wording to the specific labeled nr-axSpA indication shown in section 1.4. Remove or qualify unsupported neurologic/ocular/hepatic/malignancy/cardiovascular claims unless corresponding label text is supplied.